Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNC6989-0001 in Healthy Participants With Overweight or Obesity
NCT07437079Phase 1Recruiting
- Sponsor
- Novo Nordisk
- Start
- Feb 2026
- Primary completion
- Jan 2027
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity comparing NNC6989-0001 with Placebo (2 arms). Primary endpoints: Number of treatment emergent adverse events (TEAE) - Part A at Day 7, Number of treatment emergent adverse events (TEAE) - Part B at Day 14 and 1 more. Started Feb 2026; status: recruiting.
02
Drugs
NNC6989-0001
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07437079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07437079.